List of Excipients in Branded Drug GOOD SENSE ANTI DIARRHEAL ANTI GAS

Generic Drugs Containing GOOD SENSE ANTI DIARRHEAL ANTI GAS

Company	Ingredient	NDC	Excipient
L Perrigo Company	loperamide hydrochloride, simethicone	0113-0087	ACESULFAME POTASSIUM
L Perrigo Company	loperamide hydrochloride, simethicone	0113-0087	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
L Perrigo Company	loperamide hydrochloride, simethicone	0113-0087	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in GOOD SENSE ANTI DIARRHEAL ANTI GAS?

# Of NDCs	Excipient
2	ACESULFAME POTASSIUM
2	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
2	CELLULOSE, MICROCRYSTALLINE

# GoodSense Anti-Diarrheal Anti-Gas: Excipient Strategy, Regulatory Position and Commercial Opportunities

Last updated: September 24, 2026

GoodSense Anti-Diarrheal Anti-Gas is an OTC combination product built around loperamide hydrochloride and simethicone. The product’s commercial value comes from combining diarrhea control with gas relief in one dosage form, not from proprietary active-ingredient exclusivity. The main opportunities are private-label cost reduction, improved swallowability, differentiated excipient systems, packaging optimization, and expansion into chewable, orally disintegrating, pediatric-directed, and travel-use formats.

The core commercial constraint is intense competition from Imodium Multi-Symptom Relief and retailer-branded equivalents. A successful product strategy must preserve rapid disintegration, dose uniformity, taste acceptability, physical stability, and low manufacturing cost while avoiding excipients that create labeling, allergen, color, or tolerability concerns.

What active ingredients are in GoodSense Anti-Diarrheal Anti-Gas?

GoodSense Anti-Diarrheal Anti-Gas uses two OTC active ingredients:

Active ingredient	Typical strength	Function
Loperamide hydrochloride	2 mg	Reduces the frequency of loose stools by slowing intestinal motility
Simethicone	125 mg	Reduces gas-related pressure, bloating, and discomfort

The combination corresponds to the U.S. OTC “anti-diarrheal and gas relief” product category. Loperamide is an opioid-receptor agonist acting primarily in the gastrointestinal tract at recommended doses. Simethicone is an antiflatulent that reduces surface tension of gas bubbles in the gastrointestinal tract. The product is intended for adults and children aged 12 years and older under the labeled directions. Product labeling directs consumers to stop use and seek medical advice for specified symptoms, including bloody or black stool, fever, worsening diarrhea, or diarrhea lasting beyond the labeled period. (FDA, 2024a; DailyMed, 2024)

The product is generally positioned as a multisymptom alternative to single-ingredient loperamide products. That positioning supports a modest retail premium over basic loperamide tablets but limits the product’s ability to compete solely on unit price.

What excipients are likely used in the product?

Exact inactive ingredients depend on the GoodSense SKU, dosage form, supplier, and manufacturing site. Film-coated loperamide-simethicone tablets commonly use a conventional compressed-tablet platform with excipients selected for flow, compression, disintegration, coating, and appearance.

A representative excipient architecture is:

Excipient category	Common candidates	Commercial purpose
Diluent or filler	Microcrystalline cellulose, dibasic calcium phosphate	Provides tablet mass and compression performance
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes tablet breakup after swallowing
Glidant	Colloidal silicon dioxide	Improves powder flow and blend uniformity
Lubricant	Magnesium stearate	Prevents sticking and supports tablet ejection
Film former	Polyvinyl alcohol, hypromellose	Protects the core and improves appearance
Plasticizer	Polyethylene glycol	Improves coating flexibility
Opacifier	Titanium dioxide or equivalent pigment	Controls opacity and appearance
Colorant	Approved FD&C or D&C colorants	Supports product identification
Anti-tacking agent	Talc	Improves coating processability

The most important technical issue is balancing the high simethicone load with the low-dose loperamide component. Simethicone is hydrophobic and can complicate powder blending, wetting, dispersion, and content uniformity. The formulation must prevent simethicone agglomeration while ensuring that each unit contains the correct loperamide dose.

The excipient system also affects the product’s regulatory and commercial profile. Dyes can create consumer objections and supply-chain exposure. Titanium dioxide may create market-specific restrictions or retailer scrutiny. Lactose, gluten-containing materials, artificial sweeteners, and animal-derived excipients can affect “free-from” claims and international distribution.

How should the excipient strategy be designed?

A practical formulation strategy should prioritize five performance objectives:

1. Uniform distribution of 2 mg loperamide hydrochloride.
2. Stable dispersion of 125 mg simethicone.
3. Rapid tablet disintegration without compromising mechanical strength.
4. Low moisture uptake during storage.
5. Acceptable mouthfeel and swallowability.

Blend uniformity and simethicone dispersion

Loperamide is present at a much lower mass than simethicone and the excipients. Poor segregation control can produce content-uniformity failures. A high-shear premix, geometric dilution, ordered blending, or granulation approach can reduce this risk.

Simethicone may be introduced as an adsorbed powder, emulsion-derived solid, or coated particulate. Adsorbed simethicone can improve handling and blend uniformity. A coated or encapsulated form may improve dispersion and reduce oily mouthfeel, but it increases cost and process complexity.

Disintegration and dissolution

The product should disintegrate quickly enough to support consumer expectations while maintaining tablet hardness during packaging and transportation. Croscarmellose sodium and crospovidone are common choices because they provide rapid swelling or wicking at relatively low concentrations.

Over-lubrication with magnesium stearate can slow wetting and dissolution. This is particularly relevant in a formulation with hydrophobic simethicone. Lubricant concentration, blending time, and particle-size distribution should be tightly controlled.

Moisture management

Moisture can affect tablet hardness, coating integrity, simethicone dispersion, and chemical stability. Blister packaging provides stronger moisture protection than low-cost bottles but increases packaging cost. A high-barrier bottle with a desiccant can support a lower-cost retail format if the product is adequately protected during shelf life.

Consumer-facing excipient selection

A reformulated product could remove or reduce:

• Artificial colors
• Titanium dioxide
• Lactose
• Gluten-containing excipients
• Artificial sweeteners
• Animal-derived components

The commercial benefit is stronger positioning for sensitive-consumer segments. The trade-off is potential cost inflation, altered appearance, reduced process robustness, or lower tablet acceptability.

What dosage forms offer the strongest commercial opportunity?

The current conventional tablet platform is cost-efficient, but dosage-form innovation offers more defensible product differentiation.

Chewable tablets

Chewables are the most direct extension. They can improve access for consumers who have difficulty swallowing caplets and can support travel use. Their main technical risks are bitter loperamide taste, simethicone mouthfeel, tablet friability, and flavor stability.

A successful chewable would require taste masking through polymer coating, ion exchange, lipid barriers, sweetener systems, or multiparticulate technology. Mint, citrus, and berry flavor systems could be evaluated, but flavor must not create a medicinal or overly sweet profile.

Orally disintegrating tablets

An orally disintegrating tablet could provide a swallowability benefit without water. However, the relatively high simethicone dose creates a large tablet-mass problem. A compact ODT may be difficult unless the simethicone is highly loaded, adsorbed, or converted into a specialized particulate form.

The ODT route is technically more challenging than a chewable and may not deliver enough incremental consumer value to justify its manufacturing cost.

Softgels and liquid-filled capsules

A softgel could accommodate simethicone in a lipid-based system and potentially improve dose uniformity. It would require careful compatibility evaluation between loperamide, simethicone, fill materials, shell composition, and oxygen or moisture exposure.

Softgels also carry higher tooling and packaging costs. They are more likely to work as a premium private-label product than as the lowest-cost GoodSense configuration.

Liquid suspension

A liquid product could target consumers unable to swallow tablets, but loperamide dosing, simethicone dispersion, preservative effectiveness, flavor masking, and dose-measuring accuracy become major issues. A suspension would have greater manufacturing and stability complexity than a tablet.

What regulatory status does GoodSense Anti-Diarrheal Anti-Gas have?

GoodSense Anti-Diarrheal Anti-Gas is an OTC drug product rather than an FDA-approved new molecular entity. Loperamide and simethicone are established OTC ingredients regulated under FDA OTC monograph frameworks and applicable labeling requirements. FDA’s final OTC monograph for antidiarrheal products identifies the conditions under which covered active ingredients and labeling may be marketed without an approved new drug application. (FDA, 2024b)

The commercial implications are significant:

Regulatory issue	Impact
New drug exclusivity	Not the primary protection mechanism
OTC monograph compliance	Central to lawful U.S. marketing
ANDA pathway	Generally less relevant than monograph compliance for covered products
Clinical development	Usually unnecessary for a compliant monograph product
Labeling	Must comply with required indications, warnings, directions, and age limits
Manufacturing	Must comply with current good manufacturing practice requirements
Product listing	Required for marketed drug products
Orange Book	Usually not the central competitive registry for monograph OTC products

A reformulated version may remain within the OTC monograph framework if the active ingredients, strengths, dosage form, labeling, and other conditions remain compliant. A novel delivery system or unapproved indication could create a different regulatory pathway.

What patents protect GoodSense Anti-Diarrheal Anti-Gas?

The active ingredients do not provide a meaningful modern exclusivity barrier for this product. Loperamide and simethicone are long-established ingredients, and the commercial category contains numerous competing products.

Potential intellectual-property protection may exist around:

• Specific tablet compositions
• Taste-masking systems
• Simethicone particle engineering
• Bilayer or multilayer tablets
• Orally disintegrating systems
• Coating compositions
• Manufacturing methods
• Packaging configurations
• Brand names and trade dress

The strongest patent opportunity would involve a formulation that solves a measurable problem, such as improved loperamide taste masking, faster simethicone dispersion, reduced tablet size, better moisture stability, or enhanced content uniformity.

A basic combination of loperamide and simethicone in a conventional compressed tablet is unlikely to support durable blocking-patent protection by itself. The more realistic protection strategy is a layered portfolio combining formulation patents, process know-how, trademarks, and retailer or distributor contracts.

When does GoodSense Anti-Diarrheal Anti-Gas lose exclusivity?

The product has no conventional NCE exclusivity expiration date comparable to a prescription drug. Its competitive exposure is continuous because multiple manufacturers can market loperamide-simethicone products under OTC monograph conditions.

Protection type	Expected status
New chemical entity exclusivity	Not applicable
Prescription-drug patent exclusivity	Not applicable to the core OTC combination
OTC monograph protection	No company-specific exclusivity
Trademark protection	Applies to the GoodSense name and related branding
Formulation patents	Possible, but product-specific
Manufacturing know-how	Potentially valuable but not publicly visible
Retailer distribution position	Commercially important and contract-dependent

A competitor can enter through a retailer brand, national OTC brand, online channel, or contract-manufactured product if it satisfies the applicable FDA requirements.

What generic entry risks exist?

Generic and private-label entry risk is high. The product uses widely available active ingredients and conventional dosage-form technology. Entry barriers are primarily operational rather than legal.

The main barriers are:

• Reliable supply of pharmaceutical-grade loperamide and simethicone
• Blend uniformity at a low loperamide loading
• Stable coating and tablet appearance
• Taste and mouthfeel management
• FDA-compliant labeling
• Retailer qualification
• Demonstrated shelf-life stability
• Packaging-line compatibility
• Quality-system performance

A new supplier can often compete quickly if it has an established OTC manufacturing platform. Retailers may switch suppliers based on landed cost, fill rate, defect rates, and compliance history.

Which companies challenge GoodSense Anti-Diarrheal Anti-Gas?

The product competes with national brands, retailer brands, and single-ingredient alternatives.

Competitor class	Representative products or companies	Competitive advantage
National combination brand	Imodium Multi-Symptom Relief, Kenvue	Brand recognition and broad distribution
Retailer private label	CVS Health, Walgreens, Walmart, Target and other store brands	Lower price and shelf placement
Single-ingredient loperamide	Imodium A-D and generic loperamide products	Lower cost and simpler indication
Simethicone products	Gas-X, Mylanta Gas, private-label simethicone	Stronger gas-relief positioning
Travel and convenience products	Various OTC travel packs	Portability and packaging differentiation

The product’s best defense is not exclusivity. It is a favorable value equation: combination therapy, acceptable tablet performance, dependable supply, and a lower retail price than the national brand.

What commercial opportunities exist for excipient innovation?

Dye-free and titanium-dioxide-free products

A clean-label tablet can target consumers who avoid artificial colors or specific pigments. This opportunity is strongest in retailer brands and online channels where product descriptions can communicate formulation attributes directly.

Low-allergen formulations

A lactose-free, gluten-free, and gelatin-free product can expand consumer acceptance. These claims require supplier qualification, analytical verification, and controlled cross-contact procedures.

Smaller tablets

Reducing tablet size could improve swallowability and lower packaging volume. The technical challenge is maintaining the full 125 mg simethicone dose while preserving rapid disintegration.

Travel packaging

Unit-dose blister packs, tear strips, and compact cartons support airports, travel retailers, emergency kits, and workplace first-aid channels. Packaging is a more immediate commercial differentiator than a new excipient alone.

Pediatric-adjacent formats

A product for children under 12 would require careful regulatory and clinical assessment. The existing adult-directed product should not be repositioned for younger children solely through excipient or flavor changes. A pediatric opportunity would involve a separate dosage, labeling, and safety strategy.

E-commerce bundles

Combination packs with oral rehydration salts, wipes, travel medicine, or first-aid products could increase basket size. These bundles do not create drug exclusivity but can improve retailer economics and consumer convenience.

How does the patent position compare with competing OTC products?

Product type	Active-ingredient exclusivity	Formulation opportunity	Commercial moat
GoodSense loperamide-simethicone	Low	Moderate	Retail price and distribution
Imodium Multi-Symptom Relief	Low for actives	Moderate	Brand, recognition, distribution
Single-ingredient loperamide	Low	Moderate	Lowest cost and broad availability
Simethicone-only products	Low	Moderate	Gas-relief brand positioning
Novel chewable or ODT	Low for actives	Higher	User experience and formulation IP

A differentiated chewable, taste-masked, low-moisture, or rapid-disintegration platform has greater patent potential than a standard film-coated tablet. Patent claims should focus on measurable formulation parameters rather than merely restating the active ingredients.

What manufacturing and IP barriers matter most?

Manufacturing know-how may be more valuable than a narrow patent in this category. Critical process knowledge includes:

• Order of ingredient addition
• Premixing conditions
• Simethicone carrier selection
• Granulation endpoint
• Lubrication time
• Compression force
• Coating temperature and spray rate
• Moisture-control specifications
• In-process uniformity testing

A company pursuing private-label supply should consider a freedom-to-operate review covering formulation patents, chewable technologies, taste-masking systems, coating systems, and packaging claims. Trade-secret controls are important because process parameters may be difficult to protect through broad patent claims.

Licensing opportunities are most likely to involve formulation technology, contract manufacturing, retailer supply, flavor systems, or specialty excipient platforms. Publicly disclosed licensing deals are not central to the standard GoodSense product model.

What generic launch scenarios are most likely?

Lowest-cost conventional tablet

This is the most probable competitive scenario. A manufacturer uses standard excipients, film coating, and bottle or blister packaging. The product competes primarily on cost and retailer access.

Premium clean-label tablet

This version removes selected dyes, lactose, titanium dioxide, or animal-derived materials. It may command a modest premium but requires stronger consumer communication.

Chewable combination product

This format offers the clearest consumer-facing differentiation. Success depends on taste masking, tablet size, and acceptable simethicone mouthfeel.

Travel blister product

A compact unit-dose format could target travel, convenience, and emergency use. Its value comes from packaging and channel strategy rather than novel pharmacology.

Key Takeaways

• GoodSense Anti-Diarrheal Anti-Gas is based on 2 mg loperamide hydrochloride and 125 mg simethicone.
• The product’s core excipient challenge is combining low-dose loperamide uniformity with high-dose, hydrophobic simethicone dispersion.
• Conventional tablets have low patent barriers and high private-label competition.
• The strongest commercial opportunities are chewables, clean-label tablets, travel blisters, smaller units, and improved taste-masking systems.
• OTC monograph compliance is more important than NCE or prescription-style exclusivity.
• Formulation patents are possible but should target technical solutions, not the basic loperamide-simethicone combination.
• Manufacturing know-how, retailer contracts, packaging, and supply reliability are likely to determine commercial performance.
• A standard tablet is primarily a cost-and-distribution business; a differentiated chewable or taste-masked product offers greater margin and IP potential.

FAQs

Is GoodSense Anti-Diarrheal Anti-Gas the same as Imodium Multi-Symptom Relief?

Both products use the same core active combination of loperamide hydrochloride and simethicone at commonly marketed strengths. They may differ in inactive ingredients, tablet design, coating, packaging, labeling presentation, and manufacturing source.

Can GoodSense Anti-Diarrheal Anti-Gas be reformulated without a new FDA approval?

A reformulation may remain eligible for OTC monograph marketing if it preserves the required active ingredients, dosage, dosage form, labeling, and other monograph conditions. A materially novel delivery system or unapproved claim may require a different regulatory pathway.

Which excipient is most important for simethicone tablet performance?

The simethicone carrier or dispersion system is often the most important excipient-related variable. It affects blend uniformity, wetting, tablet compression, mouthfeel, and disintegration.

Is there a strong patent opportunity for a loperamide-simethicone chewable?

Potentially, but protection would need to center on specific technical features such as taste masking, particle engineering, excipient ratios, disintegration performance, or stability. The basic active combination is unlikely to provide broad new protection.

What is the most attractive commercial extension for this product?

A taste-masked chewable in a compact travel pack offers the clearest combination of consumer differentiation, packaging value, and potential formulation IP. A dye-free or clean-label conventional tablet is easier to manufacture but likely faces more direct price competition.

References

1. DailyMed. (2024). Loperamide hydrochloride and simethicone tablet labeling. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2024a). Over-the-counter antidiarrheal drug products: Labeling and consumer-use requirements. FDA.

3. U.S. Food and Drug Administration. (2024b). OTC monograph M009: Antidiarrheal drug products for over-the-counter human use. FDA.

4. U.S. Food and Drug Administration. (2024c). Current good manufacturing practice requirements for finished pharmaceuticals. FDA.

5. United States Pharmacopeia. (2024). General chapters and excipient standards for pharmaceutical dosage forms. United States Pharmacopeial Convention.